Granisetron (HCl)

Granisetron is an oral and parenteral antiemetic agent. Granisetron (HCl) is commonly used to treat nausea and vomiting from highly emetogenic cancer chemotherapy. The actions, uses and adverse effects similar to those of ondansetron, but unlike ondansetron, Granisetron (HCl) is not approved for postoperative emesis. Granisetron selectively blocks type 3 serotonin (5-HT3) receptors. 5-HT3 receptors are found centrally in the chemoreceptor trigger zone and peripherally at vagal nerve terminals in the intestines. Whether the action of Granisetron is mediated centrally, peripherally, or a combination of both remains to be determined. Granisetron injection was approved by the FDA on December 29, 1993. The oral dosage form was subsequently approved March 20, 1995 and has been shown to be as effective as IV ondansetron for chemotherapy-induced nausea and vomiting.

Granisetron (HCl) is primarily indicated in conditions like Nausea and vomiting (chemotherapy induced), prevention of Nausea and vomiting associated with chemotherapy, Post-operative nausea and vomiting.

Granisetron (HCl) is contraindicated in conditions like Hypersensitivity, Sub-acute intestinal obstruction.

The signs and symptoms that are produced after the acute overdosage of Granisetron (HCl) include Headache. The symptomatic adverse reactions produced by Granisetron (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Constipation, Rashes, Hypersensitivity reactions, Decreased GI motility.

Hypersensitivity reactions, including anaphylactic reaction, shortness of breath, hypotension, and urticaria, reported rarely. Possible hypersensitivity reactions in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. Does not stimulate gastric or intestinal peristalsis; do not use as a substitute for nasogastric suction. May mask progressive ileus and/or gastric distention when used in patients undergoing abdominal surgery or in those with chemotherapy-induced nausea and vomiting. Category B. Not known whether granisetron is distributed into milk. Caution advised if used in nursing women. Safety and efficacy of IV granisetron for chemotherapy-induced nausea and vomiting not established in children <2 years of age; safety and efficacy of IV granisetron for prevention and treatment of postoperative nausea and vomiting not established in children of any age. Safety and efficacy of oral granisetron not established in children of any age. No substantial differences in safety and efficacy for chemotherapy-induced nausea and vomiting in geriatric patients relative to younger adults. Insufficient experience with IV granisetron for postoperative nausea and vomiting in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.

Hypersensitivity reactions, including anaphylactic reaction, shortness of breath, hypotension, and urticaria, reported rarely. Possible hypersensitivity reactions in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. Does not stimulate gastric or intestinal peristalsis; do not use as a substitute for nasogastric suction. May mask progressive ileus and/or gastric distention when used in patients undergoing abdominal surgery or in those with chemotherapy-induced nausea and vomiting. Category B. Not known whether granisetron is distributed into milk. Caution advised if used in nursing women. Safety and efficacy of IV granisetron for chemotherapy-induced nausea and vomiting not established in children <2 years of age; safety and efficacy of IV granisetron for prevention and treatment of postoperative nausea and vomiting not established in children of any age. Safety and efficacy of oral granisetron not established in children of any age. No substantial differences in safety and efficacy for chemotherapy-induced nausea and vomiting in geriatric patients relative to younger adults. Insufficient experience with IV granisetron for postoperative nausea and vomiting in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.

3 mg (3 (3)) As recommended. IV-Inf (over 5 min) — Prevention, before start of chemotherapy (up to 2 additional doses may be given within 24 hrs). 3 mg (3 (3)) As recommended. Iv-Inf (over 5 min) — Treatment, as for prevention (the two additional doses must not be given

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

Apparently metabolized by CYP3A; does not induce or inhibit CYP isoenzymes.

Inj (reconstituted soln) Store at room temperature. Use within 24 hrs if kept at room temperature. IV Inj, IV Inf, Oral Soln Store at room temperature, Below 30°C. Do not Freeze. Protect from Sunlight. Tab Store at room temperature. Protect from Sunlight.